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Background: Chronic Obstructive Pulmonary Disease (COPD) is a growing worldwide problem that imposes a
great burden on the daily life of patients. Since there is no cure, the goal of treating COPD is to maintain or
improve quality of life. We have developed a new tool, the Assessment of Burden of COPD (ABC) tool, to assess
and visualize the integrated health status of patients with COPD, and to provide patients and healthcare providers
with a treatment algorithm. This tool may be used during consultations to monitor the burden of COPD and to
adjust treatment if necessary. The aim of the current study is to analyse the effectiveness of the ABC tool compared
with usual care on health related quality of life among COPD patients over a period of 18 months.
Methods/Design: A cluster randomised controlled trial will be conducted in COPD patients in both primary and
secondary care throughout the Netherlands. An intervention group, receiving care based on the ABC tool, will be
compared with a control group receiving usual care. The primary outcome will be the change in score on a
disease-specific-quality-of-life questionnaire, the Saint George Respiratory Questionnaire. Secondary outcomes will
be a different questionnaire (the COPD Assessment Test), lung function and number of exacerbations. During the
18 months follow-up, seven measurements will be conducted, including a baseline and final measurement. Patients
will receive questionnaires to be completed at home. Additional data, such as number of exacerbations, will be
recorded by the patients’ healthcare providers. A total of 360 patients will be recruited by 40 general practitioners
and 20 pulmonologists. Additionally, a process evaluation will be performed among patients and healthcare
providers.
Discussion: The new ABC tool complies with the 2014 Global Initiative for Chronic Obstructive Lung Disease
guidelines, which describe the necessity to classify patients on both their airway obstruction and a comprehensive
symptom assessment. It has been developed to classify patients, but also to provide visual insight into the burden
of COPD and to provide treatment advice.
Trial registration: Netherlands Trial Register, NTR3788.
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The prevalence of Chronic Obstructive Pulmonary Disease
(COPD) is increasing globally due to an aging popula-
tion and continued exposure to risk factors [1]. COPD
has a major impact on the lives of patients’. The preva-
lence of COPD is expected to increase, and is projected to
be the fourth leading cause of death and the seventh lead-
ing cause of disability-adjusted life years (DALYs) lost
worldwide by 2030 [2,3].
Since there is no cure for the disease, the goal of COPD
treatment is to maintain or improve patients’ quality of
life. As such, the care of patients with COPD is currently
shifting towards a more patient-centred model. More at-
tention is paid to the impact of the disease on the patient’s
life [1]. It is therefore necessary to focus on more than just
airway obstruction, as measured by the forced expiratory
volume in one second (FEV1), which has a poor correl-
ation with many patient reported outcomes in COPD [4].
Health status measurements have been propagated as an
important part of managing COPD, both in primary and
secondary care [5]. Previous studies showed that a poor
health status is a predictor for hospitalization and mortal-
ity [6-8].
Health status questionnaires can also be used to deter-
mine the burden of COPD as experienced by patients.Figure 1 Visualization of the dimensions influencing integrated healt
after treatment.However, current health status questionnaires do not fully
cover patients’ experienced burden of disease [9]. Hence,
we developed a new tool, the Assessment of Burden of
COPD (ABC) tool, which consists of three elements. The
first element is the ABC scale, a 14-item questionnaire that
measures five different domains of the burden of disease as
experienced by the patient: symptoms, functional state,
mental state, emotional state, and fatigue. The second elem-
ent comprises a number of additional indicators: smoking
status, exacerbation history, dyspnoea, body mass index
(BMI), lung function and physical activity. When combined
with the ABC scale an overall assessment of a patient’s inte-
grated health status is obtained. The third element is a
computer program used to visualize the scores on all items
into green, orange and red balloons and link treatment ad-
vice to these balloons (see Figure 1) [9].
The purpose of the ABC tool is to assess the experi-
enced burden of disease and to provide both patient and
healthcare provider with a visual overview of the individ-
ual patient’s burden of COPD. The tool is designed to fa-
cilitate shared decision making, in which patients and
healthcare providers are both responsible for the focus of
treatment , selecting the corresponding treatment options,
formulating a personal goal and make a tailored treatment
plan [10]. Patients need to be encouraged to take the leadh status (Assessment of Burden of COPD tool), changed
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in this process. It can be used during consultations to
monitor the patient’s integrated health status, including
the experienced burden of COPD, and to treat the patient
accordingly.
The development of the tool has been described else-
where [9].
The reliability, validity and responsiveness of the ABC
scale, the first element and core component of the ABC
tool, still needs to be assessed. The scale is based mainly
on the Clinical COPD Questionnaire (CCQ) [11], so we
assume that it is a valid and reliable instrument. However,
to be thorough we will analyse the internal consistency
and test-retest reliability. Furthermore, we will analyse the
convergent validity, divergent validity, known-group dif-
ferences and responsiveness.
Since the effectiveness of the ABC tool has not yet been
tested, we will conduct a cluster randomised controlled
trial (RCT). The trial will take place in both primary and
secondary care settings, to include patients with varying0 months
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Figure 2 Flow of the study.disease severity. We aim to evaluate the effectiveness by
answering the following research question:
In COPD patients, varying in disease severity, does ap-
plication of the ABC-tool increases the percentage of pa-
tients with a clinically relevant improvement on the Saint
George Respiratory Questionnaire (SGRQ) [12], between
baseline and 18 months follow-up, as compared with
usual care?
Methods/Design
Study design
The study is a two-armed cluster RCT that compares an
intervention group, using the ABC tool with a control group
receiving usual care. The duration of follow-up period is
18 months. During this period there are seven measure-
ments, including a baseline and final measurement. The
flow of the study is presented in Figure 2.
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This study will take place in general practices and hospi-
tals throughout the Netherlands. The researchers will
contact general practitioners (GPs) and pulmonologists
using a GP network (CAHAG; COPD and Asthma GP
Advice Group) and the pulmonologists association (NVALT;
Dutch Association of Physicians for Lung Diseases and
Tuberculosis). To avoid contamination of care (i.e. pa-
tients from the control group receiving the intervention
because they are treated by the same caregiver), it is vital
that the randomisation between the groups takes place at
caregiver-level and not at patient-level. Therefore, health-
care providers will be randomly assigned to intervention
or control group in a 1:1 ratio with the help of a computer
program designed by the Maastricht University Centre for
Data and Information Management (MEMIC). Random-
isation will be stratified by type of caregiver (GP or pulmo-
nologist) and variable blocks of two, four or six will be
used to make sure there are an equal number of caregivers
from primary and secondary care in the intervention and
control group. The researcher will enter the names of the
healthcare providers into the computer program, which
will then randomly allocate them to either the interven-
tion or control group.
Participating healthcare providers will be asked to invite
patients from their listed patient databases to participate
in the trial. Patients that meet the inclusion criteria and
exclusion criteria (see next paragraph) will be sent an in-
formation letter including an informed consent form.
Healthcare providers will also directly invite patients to
participate if they see them during consultations. If the pa-
tient agrees to participate in the study, an appointment
will be made with the healthcare provider to discuss fur-
ther details of the trial, recheck whether the patient is eli-
gible for the study and sign the informed consent form.
Inclusion and exclusion criteria
The inclusion criteria will be: a confirmed diagnosis of
COPD (post-bronchodilator FEV1/Forced Vital Capacity <
0.7) by spirometer, age 40 years or above, and the ability
to understand and read the Dutch language. The exclusion
criteria will be: an exacerbation less than six weeks ago,
hard-drug addiction, life-threatening co-morbid condi-
tions, and current pregnancy. Exacerbations are defined as
an acute event characterized by worsening of a patient’s
respiratory symptoms beyond normal day-to-day variation
that necessitates prednisolone and/or hospital admissions
for COPD.
Intervention group
The actual intervention will be the use of the ABC tool by
patients and healthcare providers during routine consulta-
tions. Patients will fill out the ABC scale, which measures
the patient’s experienced burden of COPD, in the waitingroom (without supervision) [9]. The healthcare provider
will then enter the results of the ABC scale into a com-
puter program and add the results of additional items
(i.e. smoking status, exacerbation history, dyspnoea,
body mass index (BMI), lung function and physical activ-
ity). These items and the ABC scale together will show the
integrated health status of the patient, illustrated by a vis-
ual representation with coloured balloons. The balloons
represent all of the patient’s health status items, including
the different domains of the ABC scale (see Figure 1).
A high, green balloon means that the patient scores well
on a particular item/domain; an orange balloon means an
intermediate score; and a low, red balloon means that the
patients scores poorly on that item/domain. Patients and
healthcare providers will be prompted to discuss the
balloons together, according to the principles of shared
decision making (SDM) [13], and will be advised to work
on the items represented by the red and orange balloons.
These represent the items with possible room for im-
provement if the right treatment is provided. Each balloon
can be clicked on, showing a pop-up with treatment
advice.
The algorithm behind the ABC tool was developed
based on a previous treatment algorithm attached to
the CCQ [14], and optimized for this study according
to national and international guidelines [15-17]. The
cut-off points are based on the current Dutch COPD
Healthcare Standard guidelines [18], and experts’ experi-
ences. The level of the balloon was determined by using a
continuous scale to grade the displayed value. The treat-
ment recommendations were written by pulmonologists
and GPs based on the current national COPD guide-
lines. Two versions of the algorithm were written, one
for the use in primary care, based on the standard of
the Dutch College of General Practitioners [15] and the
other for the use in secondary care, based on the NVALT
guidelines [16]. The treatment advice was written during
a number of meetings and groups discussions, and the
algorithm was tested extensively by healthcare providers
with different backgrounds throughout the Netherlands. Ex-
amples of the treatment advice are provided in Additional
file 1.
According to the principles of shared decision making,
patients and healthcare providers will be advised to dis-
cuss the possible treatment options within the patient’s
possibilities. One or more pieces of advice can be se-
lected and will automatically and electronically be placed
in the patient’s written treatment plan. During the con-
sultation, healthcare providers should guide patients in
setting a personalized treatment goal. This personal goal
should be written down as an achievable goal, in the pa-
tient’s own words. The treatment plan aims to achieve
the personal goal. At each follow-up moment, the inter-
vention group will complete the ABC scale and use the
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and the balloons from the previous consultation, displayed
in grey (Figure 1). The tool can be used to monitor a pa-
tient’s integrated health status over time and adjust the
treatment as necessary.
Control group
The ABC scale and tool (including its software) will only
be provided in the intervention group. The patients in the
control group will receive care as usual and their health-
care providers will not be instructed by the research team.
Measurements
Intervention group
Patients in the intervention group will receive individu-
alized treatment guided by their integrated health status,
as measured predominantly by the ABC scale. Patients
will visit their healthcare providers at least four times
during the 18 months follow-up. During these consulta-
tions, healthcare providers will record lung function,
number of exacerbations in the previous year and since
previous visit, smoking behaviour, BMI and comorbidity.
Additional file 2 shows all items of the integrated health
status. Questionnaires will be sent to patients’ homes at
0, 3, 6, 9, 12, 15 and 18 months (see Table 1).
Control group
Patients in the control group will receive care as usual.
The patients will visit their healthcare provider for the
baseline measurement (0 months) and the 18-month fol-
low up. At these consultations lung function and BMI will
be measured, and smoking status, comorbidity, number of
exacerbations in the previous year and since previous visit
will be monitored. Questionnaires will be sent to patients’
homes at 0, 3, 6, 9, 12, 15 and 18 months (see Table 1).Table 1 Measuring moments
Time (m
Completed by patients at the GP practice or hospital 0
Assessment of burden of COPD scale* x
Medical Research Council* x
Physical activity* x
Completed by patients at home
Demographics x
The Saint George Respiratory Questionnaire x
COPD Assessment Test x
EuroQol5d-5 level Questionnaire x
Patients Assessment Chronic Illness Care questionnaire x
Healthcare use, medication use x
Employment status, absence from paid work x
*Completed by patients in the intervention group only.Outcomes
Primary outcome
The primary outcome measure will be the proportion of
patients in the intervention group with a clinically mean-
ingful improvement on the SGRQ [19], that is, a decrease
of at least 4 points between baseline and 18 month follow-
up, compared with the control group.
The SGRQ consists of 50 questions with scores that
range from 0 (best) to 100 (worst). Higher scores indi-
cate more advanced impairment in health-related quality
of life [12].
Secondary outcomes
1. The net proportion of patients in the intervention
group with a clinically meaningful change of 4
points on the SGRQ between baseline and 18 month
follow-up [19], compared with the control group.
The net proportion will be calculated by subtracting
the percentage of patients improved by 4 points on
the SGRQ from the percentage of patients decreased
by 4 points.
2. The difference in the proportion of patients from
the intervention group and control group with a
clinically meaningful improvement of at least 4
points on the SGRQ (a decrease in the SGRQ
score), between baseline and 6 months and between
baseline and 12 months follow-up.
3. The absolute difference SGRQ score at 18-month
follow-up between the intervention group and
control group.
4. Health related quality of life will also be measured
by the COPD Assessment Test (CAT) [20].
Differences on total scores will be calculated
between baseline and 12 months follow-up andonths)
3 6 9 12 15 18
x x x
x x x
x x x
x
x x x
x x x
x x
x x
x x x x x x
x x x x x x
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CAT is an eight item questionnaire with scores
ranging from 0 to 40, with higher scores indicating
greater impairment of health related quality of life [20].
Differences in number of exacerbations and lung
function, as recorded by the healthcare providers,
will be calculated between the two groups, with
respect to the number of exacerbations at a given
time point and to change over time.
5. An economic evaluation will be performed at 6 and
12 months. This evaluation will compare differences
in costs with differences in effects (Cost Effectiveness
Analysis) and quality adjusted life years (Cost Utility
Analysis).
Questionnaires will be used to record visits to
physicians and healthcare providers, medication use,
hospital admissions, employment status and absence
from paid work every three months. For the
economic evaluation, costs will be calculated from a
healthcare perspective and a societal perspective.
The EuroQol5d-5 level Questionnaire (EQ-5d-5 L)
measures the generic health-related quality of life.
The EQ-5D-5 L consists of 5 dimensions to describe
health - mobility, self-care, every day activities, pain/
discomfort and anxiety/depression - each with five
levels of functioning (e.g. no problems, slight problems,
moderate problems, severe problems, unable to/severe
problems) [21]. The domain descriptions are combined
with population-based values to derive a health utility
index [22]. In addition to the descriptive system and
the off-the-shelf value sets, the EQ-5D-5 L includes
a visual analogue scale (VAS) that individuals can
use to rate their own health on a scale from 0 (worst
imaginable health) to 100 (best imaginable health).
6. The process evaluation will consist of two parts:
patients’ evaluation of the level of integrated
healthcare will be measured at baseline, 12 months
and the final visit (18 months), using the Patients
Assessment Chronic Illness Care questionnaire
(PACIC) [23]. The PACIC is a 20 item
questionnaire, with a five point response scale
(ranging from 1 = ‘almost never’ to 5 = ‘almost
always’). Higher scores represent a more frequent
presence of the aspect of structured chronic care.
Furthermore, treatment plans (recorded in the ABC
tool) will be compared qualitatively with the
delivered care to patients (as reported by the
patients).
A process evaluation among healthcare providers
includes assessing factors that may have hindered
or facilitated the implementation of the ABC
tool in the management of COPD care. This
evaluation, among approximately 10 to 15
participating healthcare providers, will be performedby means of semi-structured group interviews and
individual interviews. Questions that will be discussed
include; “How easy is it to use the ABC-tool?”, “How
did patients react on the visual display?”, and “What
barriers did you encounter when using the ABC scale
and the ABC tool?”. The methods for the process
evaluation will be described elsewhere in more detail.Sample size calculation
The required sample size of 360 patients (180 patients
per arm) is based on the following assumptions:
1) A clinical response (a clinically meaningful
improvement of at least 4 points [19]) of 50% in the
treated arm versus 30% in the control arm [24,25]
(implying an effect size d = 0.42 for the clinical
response), and a power of 80% to detect a difference
in the clinical response rate of the primary outcome
between the treated and control arm with a two-tailed
alpha of 5%. This assumption gives a sample size of
180 patients in total (90 patients per arm), ignoring at
first the design effect due to clustering of patients
within physicians.
2) The number of participating GPs will be about twice
as large as the number of pulmonologists.
3) An estimated availability of 5 patients per GP and
8 patients per pulmonologist on average. This,
together with assumptions 1 and 2, gives a total of
20 GPs and 10 pulmonologists. However, the
following three steps result in a sample size which is
twice as large, that is 40 GPs and 20 pulmonologists.
4) An intraclass correlation coefficient (ICC) of 0.05,
meaning that about 5% of the total outcome
variation within each arm is between GPs and
between pulmonologists, instead of between patients
of the same physician. Literature suggests that an
ICC of 0.05 is a good default value for trials in
primary care [26-28]. Combined with assumptions
2 and 3, and allowing for 10% more clusters
(healthcare providers) to compensate the power loss
due to variation in cluster size, that is, in number
of patients included per healthcare provider, this
ICC of 0.05 implies a design effect of 1.38 [29].
The number of clusters must thus be multiplied
with 1.38.
5) A dropout rate of 25% of patients and/or clusters,
to be compensated by multiplying the number of
clusters to be included by 1.33 (since 75% of 1.33
is 1). Dropouts will be included into the analyses
(intention to treat), but contribute less to the power
due to missing data, hence the present correction.
6) Data analysis of the primary outcome with the
recommended PQL2 (penalized quasi-likelihood)
estimation method which requires a further
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factor of 1.10 [30].
Combining assumptions 4, 5 and 6 gives a multiplica-
tion factor of 1.38 * 1.33 * 1.10 = 2 for the number of GPs
and pulmonologists as computed in steps 1 to 3, leading
to the planned sample size of 40 GPs, 20 pulmonologists
and 360 patients in total.
Statistical analysis
All baseline variables and outcomes will be summarized
with descriptive tables and, in the case of repeated mea-
sures, plotted against time per treatment arm.
The primary and first two secondary outcomes are bin-
ary outcomes and will be analysed with mixed logistic re-
gression, using PQL2 or numerical integration as method
of estimation.
All quantitative outcomes will be analysed with mixed
linear regression, with physician, patient and measurement
as three levels at which sampling error occurs, and as pre-
dictors treatment arm, time point of measurement, treat-
ment by time interaction, patient demographics and other
prognostic variables. Generalized linear mixed models with
negative binomial distribution will be used to estimate the
adjusted difference in exacerbations. Costs will also be
analysed with generalized linear mixed models using a
log-normal distribution or gamma distribution. A p-value
of < .05 will be considered statistically significant.
All data will be analysed according to the intention-to-
treat principle, including all randomised healthcare pro-
viders and patients. To prevent missing data, patients
will receive reminders for the questionnaires if they do
not return the questionnaire within three weeks. If ne-
cessary, multiple imputation to cope with missing values
will be used [31].
Discussion
This paper describes the design of a cluster RCT to evalu-
ate the effectiveness of the newly developed ABC tool. The
development of the tool was based on the insight that the
severity of COPD has to be determined by both the sever-
ity of the airway obstruction and the burden of disease.
The 2014 guidelines of the Global Initiative for Chronic
Obstructive Lung Disease (GOLD), recommend a compre-
hensive symptom assessment in determining the severity
of COPD [17]. The guidelines also introduced a combined
COPD assessment resulting in an ABCD classification.
This novel classification integrates symptom severity as
measured by mMRC [32], CCQ [11] of CAT [20], versus
prognostic indicators of pathophysiologic severity assessed
by airflow obstruction and exacerbation history [33]. The
ABC tool offers a different operationalization of this new
approach and goes beyond classification. The strength of
the tool is that it provides a profile of scores on manydifferent domains of COPD-related health. The tool
not only focuses on the quantification of the burden of
COPD, but determines the actual integrated health status.
In addition, it provides a treatment algorithm which gives
the patient and healthcare provider insight into treat-
ment options accordingly. The tool offers a visual dis-
play of the integrated health status using balloons to show
the scores on the different domains of the ABC scale and
additional items such as smoking status and exacerbation
history. Furthermore, the algorithm provides treatment
advice, including pharmacologic options as well as non-
pharmacologic options, to formulate a personalized treat-
ment goal and treatment plan. The tool is designed
to provide insight into the patient’s individual burden
of COPD and therefore enables to make a tailored treat-
ment plan and to make the patient feel co-responsible for
their own treatment, using principles of shared decision
making [13].
An important issue during the process of designing the
study was the selection of an appropriate primary outcome
measure. It is more common to use objective parameters,
such as the airway obstruction, as primary outcomes [34].
However, airway obstruction is hypothesized to correl-
ate poorly with health status and/or quality-of-life [4].
We therefore decided to use a health-related quality-
of-life questionnaire. Since treatment in the interven-
tion arm is based on the outcomes of this new instrument,
which is based on the CCQ, a different quality-of-life in-
strument will be used to measure the primary outcome.
We decided to use the SGRQ [12], a disease-specific
quality-of-life instrument. We hypothesize that the
use of the ABC tool in daily care will have a positive
effect on the quality-of-life of COPD patients As the CAT
is part of the assessment according to the GOLD guide-
lines [17], we decided to use it as a secondary outcome
measure.
The trial will be conducted throughout the Netherlands,
in both primary and secondary care. This will make it
possible to evaluate the effectiveness of the ABC tool on
the health status of patients with different COPD sever-
ities. Conducting the study in many clusters throughout
the Netherlands might lead to a higher external validity
of the results. Furthermore, it might help facilitating
the process of implementation. If the results of this trial
are as expected, it will be advised to implement the ABC
tool in routine care. To facilitate this, it is recom-
mended to adopt the tool in the registration systems of
healthcare providers and in healthcare standards. Using
the tool in routine care provides structure in each con-
sultation, and more insight for patients in all factors
related to COPD. It might help healthcare providers
to discuss difficult issues with their patients related to
COPD, such as emotions, smoking cessation and im-
pact of COPD on daily life. Furthermore, it might lead to
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their own treatment, increasing their self-management.
Additional files
Additional file 1: Examples of treatment advice in the algorithm.
Additional file 2: Integrated Health Status.
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